LETTERS

augeberg et al recently published clinical decision rules to identify patients with rheumatoid arthritis (RA) at risk for osteoporosis.1 Included were patients treated with glucocorticoids, a subject that has been for a long time the interest of rheumatologists.2–4 For example, the Dutch Society for Rheumatology has recently published guidelines for the prevention of glucocor-ticoid induced osteoporosis (GIOP).5 This document was prepared by a group of rheumatologists of the society and other experts to mark the occasion of the publication of the 3rd Osteoporosis Guideline, (the ‘‘CBO consensus’’) which was, in turn, prepared at the request of the Dutch authorities by a multidisciplinary group who examined evidence based medicine.6 Figure 1 is a stream diagram showing the diagnostic an